TG Therapeutics Raises $60m Following Combo Therapy Success In CLL

 
• By Joseph Haas

One day after reporting that its umbralisib/ublituximab combo met a PFS endpoint in CLL, TG raises $60m as it prepares for a year-end filing of the combo. Umbralisib monotherapy is under FDA review already.

Winning, victory, success and surviving concept. Green board game pawn stand alone, the white rest fallen. Eliminating competitors. One against the others. Last man standing. Against all odds.
TG Therapeutics' U2 combo topped a comparator regimen for PFS in CLL patients

More from Clinical Trials

More from R&D